Device Trial Radar · NCT03902496
Optical Treatment of Migraines Using the Avulux™ Optical Filter in the Form of Spectacle Lenses.
Last checked: Nov 20, 2026Latest source record: Jul 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Mar 18, 2019
Primary completion
May 17, 2019
Study completion May 17, 2019
Sponsor
- Lead sponsor
- Avulux, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 4, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of the Avulux device in reducing the impact of migraine headaches as measured by improvement in Headache Impact Test (HIT-6TM) scores at three weeks when compared to a control/sham device.
Conditions
- Migraine
Interventions
HIT-6 QuestionnaireOther
Headache Impact Test
Avulux SpectaclesDevice
Avulux™ Optical Filter in the Form of Spectacle Lenses
Sham SpectaclesDevice
Sham
Primary outcomes
What the sponsor says the trial is designed to measure.
- Headache Impact Test (HIT-6) total scoreTime frame: Three-week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Remington-Davis Clinical Research
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.